Alexion in Canada

Alexion is focused on providing innovative treatments to patients with severe and life-threatening rare diseases for which there are few, if any, effective treatment options.

In 2009, Alexion began operations in Canada to serve patients locally. Soliris received marketing authorization from Health Canada for all patients with PNH that same year. Soliris was then approved by Health Canada in 2013 as safe and effective for use in children and adults with atypical HUS to inhibit complement-mediated thrombotic microangiopathy (TMA).1

Our approach to serving patients is driven by education and a passion for understanding and meeting the unique needs of patients and families suffering with ultra-rare diseases. These include disease education programs to raise awareness among physicians, and diagnostic initiatives to reduce the multi-year delays that patients with ultra-rare diseases often face, even when a safe and effective therapy is available. By expanding the knowledge and awareness of PNH and atypical HUS, our teams help the medical community improve diagnosis and treatment of severe, life-threatening diseases, with the goal of improving patient outcomes.

To further advance the understanding of PNH and atypical HUS in the Canadian population, Alexion Canada sponsors disease registries that enrol treated and untreated patients who are diagnosed with these conditions. This is our commitment to ongoing research into the rare conditions that our therapies treat.

Alexion is currently conducting multiple clinical trials in Canada for treatments in new therapeutic areas. Our focus is on disorders that are severely debilitating and life-threatening for which our therapeutic candidates have the potential to provide a life-transforming impact. We are committed to the safety of patients who take part in our trials, and uphold the highest ethical standards in all of our research initiatives.

References
1. Soliris indicated for atypical HUS in children less than 13 years of age and /or weighing less than 40 kg, has been issued marketing authorization with conditions (NOC/c) pending the results of studies to verify its clinical benefits. Patients should be advised of the nature of the authorization. For further information please refer to Canadian Product Monograph.